Anti-human VLDL receptor Antibody Monoclonal, VR-VL9E11

ORDERING INFORMATION

Catalog Number: BML032

Lot Number:

Size: 50 μg

Formulation: 0.2 μm filtered PBS solution

Storage: -80˚C

Specificity: human VLDL receptor

Immunogen: synthetic peptide

Ig Type: IgG2b

Application: Western blot

Flowcytometry

Immunohistochemistry

Preparation

Produced in mice immunized with synthetic peptides, amino acid residue 200-214 (SLEQCGROPVIHTKC), which is corresponding to the linker site of ligand binding domain of human very low-density lipoprotein (VLDL) receptor (VLDL-R). VLDL-R specific IgG was purified from mouse ascites fluid with a protein A-Sepharose.

Formulation

0.2 μm filtered PBS solution

Storage

IgG in PBS solution are stable for twelve months from the date of receipt when stored at -80˚C. Avoid repeated freeze-thaw cycles.

Specificity

This antibody has been selected for its ability to bind for human VLDL-R expressed in CHO cells (*ldl-A7*). No cross-reactivity with human LDL receptor and apoER2 receptor was confirmed (see ref. 1). The amino acid sequence of synthetic peptide is identical to that in mouse, rat and rabbit, indicating that this antibody may crossreact with VLDL receptor in those amimals.

Additional Applications

Western Blot - This antibody can be used at 1.0 μg/mL for western blot analysis (1).

Flow cytometry - This antibody can be used as a 1st antibody for immunohistochemistry. Please see the references (2) and (3) for details.

Immunohistochemistry - This antibody can be used for immunohistochemistry (4).

Optimal dilutions should be determined by each laboratory for each application.

References

(1) Kosaka et al., Evidence of macrophage form cell formation by very low-density lipoprotein receptor: Interferon-γ inhibition of very low-density lipoprotein receptor expression and form cell formation in macrophages. Circulation, 2001;103:1142-1147.

(2) Iwasaki et al., The important role for ßVLDLs binding at the forth cysteine of first ligand-binding domain in the low-density lipoprotein receptor. J Hum Genet, 2004;49:622-628.

(3) Iwasaki et al., Deficiency of the very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor. Endocrinology, 2005;146:3286-3294.

(4) Motoi et al., Apolipoprotein E receptor 2 is involved in neurotic plaque formation in APP sw mice. Neurosci Lett, 2004;368:144-147.

BML, Inc.

1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan

TEL +81-49-232-0440/FAX +81-49-232-5480